Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Morphine sulfate
RN: 64-31-3
UNII: DY70C97N30
InChIKey: USAHOPJHPJHUNS-IFCNUISUSA-N

Note

  • The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle.

Molecular Formula

  • C17-H19-N-O3.1/2H2-O4-S

Molecular Weight

  • 668.76
 

Classification Codes

  • Analgesic (Narcotic)
  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
  • Reproductive Effect
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Regulatory Agencies (Superlist Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Results Name

  • Morphine sulfate

Name of Substance

  • Morphine sulfate (anhydrous)

Synonyms

  • Arymo ER
  • Astramorph
  • Astramorph PF
  • Avinza
  • Duramorph
  • Duramorph PF
  • EINECS 200-582-8
  • Infumorph
  • Kadian
  • Kapanol
  • l-Morphine sulfate
  • Morphabond
  • MorphaBond ER
  • Morphine sulfate
  • Morphine sulphate
  • Morphine, hemisulfate
  • MS Contin
  • MST
  • MST-1 Continus
  • NIH 0001
  • NIH 10753
  • NSC 11441
  • Oramorph SR
  • Skenan
  • UNII-DY70C97N30

Systematic Names

  • Morphinan-3,6-alpha-diol, 7,8-didehydro-4, 5-alpha-epoxy-17-methyl-, sulfate
  • Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-, sulfate (2:1) (salt)
  • Morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl-, sulfate (2:1) (salt)
  • Morphine sulphate

Mixture Name

  • Embeda

Registry Numbers

CAS Registry Number

  • 64-31-3

FDA UNII

  • DY70C97N30

Other Registry Numbers

  • 1095-53-0
  • 178935-96-1

Related Registry Number

  • 57-27-2 (Parent)

System Generated Number

  • 0000064313

Molecular Formulas

Molecular Formula

  • C17-H19-N-O3.1/2H2-O4-S

Molecular Formula Fragments

  • C17-H19-N-O3
  • COMPONENT
  • H2-O4-S

Structure Descriptors

InChI

InChI=1S/2C17H19NO3.H2O4S/c2*1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18;1-5(2,3)4/h2*2-5,10-11,13,16,19-20H,6-8H2,1H3;(H2,1,2,3,4)/t2*10-,11+,13-,16-,17-;/m00./s1

InChIKey

USAHOPJHPJHUNS-IFCNUISUSA-N

Smiles

CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@@H]2C=C[C@@H]4O)c35.CN6CC[C@]78[C@H]9Oc%10c(O)ccc(C[C@@H]6[C@@H]7C=C[C@@H]9O)c8%10.OS(=O)(=O)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
chicken LDLo intravenous 125mg/kg (125mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)		 Archives Internationales de Pharmacodynamie et de Therapie. Vol. 79, Pg. 282, 1949.
dog LD50 intravenous 316mg/kg (316mg/kg) BEHAVIORAL: SLEEP

BEHAVIORAL: ANALGESIA		 Archives Internationales de Pharmacodynamie et de Therapie. Vol. 149, Pg. 571, 1964.
duck LD50 intravenous 213mg/kg (213mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)		 Archives Internationales de Pharmacodynamie et de Therapie. Vol. 79, Pg. 282, 1949.
frog LD50 parenteral 678mg/kg (678mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: CHANGES IN PSYCHOPHYSIOLOGICAL TESTS		 Archives Internationales de Pharmacodynamie et de Therapie. Vol. 79, Pg. 282, 1949.
frog LD50 subcutaneous 677mg/kg (677mg/kg)   Annals of the New York Academy of Sciences. Vol. 51, Pg. 83, 1948.
guinea pig LD50 subcutaneous 391mg/kg (391mg/kg)   Annals of the New York Academy of Sciences. Vol. 51, Pg. 83, 1948.
guinea pig LDLo intramuscular 400mg/kg (400mg/kg)   JAMA, Journal of the American Medical Association. Vol. 63, Pg. 469, 1914.
guinea pig LDLo oral 1gm/kg (1000mg/kg)   JAMA, Journal of the American Medical Association. Vol. 63, Pg. 469, 1914.
hamster LD50 subcutaneous 1250mg/kg (1250mg/kg)   Proceedings of the Society for Experimental Biology and Medicine. Vol. 54, Pg. 339, 1943.
man TDLo oral 12mg/kg/4W-I (12mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)		 Drug Intelligence and Clinical Pharmacy. Vol. 22, Pg. 397, 1988.
mouse LD50 intracrebral 5100ug/kg (5.1mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Journal of Pharmacology and Experimental Therapeutics. Vol. 140, Pg. 155, 1963.
mouse LD50 intramuscular 334mg/kg (334mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)		 Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971.
mouse LD50 intraperitoneal 275mg/kg (275mg/kg) BEHAVIORAL: ANALGESIA Journal of Medicinal Chemistry. Vol. 10, Pg. 627, 1967.
mouse LD50 intravenous 156mg/kg (156mg/kg) BEHAVIORAL: REGIDITY

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Journal of Pharmacology and Experimental Therapeutics. Vol. 157, Pg. 185, 1967.
mouse LD50 oral 600mg/kg (600mg/kg) BEHAVIORAL: ANALGESIA Journal of Pharmacology and Experimental Therapeutics. Vol. 133, Pg. 400, 1961.
mouse LD50 subcutaneous 180mg/kg (180mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)		 Australian Veterinary Journal. Vol. 49, Pg. 525, 1973.
pigeon LD50 intravenous 321mg/kg (321mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: ATAXIA		 Archives Internationales de Pharmacodynamie et de Therapie. Vol. 79, Pg. 282, 1949.
rat LD50 intramuscular 78mg/kg (78mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"		 Archives Internationales de Pharmacodynamie et de Therapie. Vol. 190, Pg. 124, 1971.
rat LD50 intraperitoneal 235mg/kg (235mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Acta Pharmacologica et Toxicologica. Vol. 22, Pg. 241, 1965.
rat LD50 intravenous 70mg/kg (70mg/kg)   Toxicology and Applied Pharmacology. Vol. 17, Pg. 250, 1970.
rat LD50 oral 461mg/kg (461mg/kg)   British Journal of Pharmacology and Chemotherapy. Vol. 30, Pg. 11, 1967.
rat LD50 subcutaneous 108mg/kg (108mg/kg) ENDOCRINE: OTHER CHANGES British Journal of Pharmacology and Chemotherapy. Vol. 10, Pg. 260, 1955.
women TDLo oral 8mg/kg (8mg/kg) BEHAVIORAL: ANALGESIA Lancet. Vol. 1, Pg. 573, 1987.

Physical Properties

Physical Property Value Units Temp (deg C) Source
Melting Point 250 deg C   EXP
log P (octanol-water) 0.720 (none)   EST
Water Solubility 6.45E+04 mg/L 25 EXP
Vapor Pressure 1.69E-09 mm Hg 25 EST
Henry's Law Constant 1.33E-16 atm-m3/mole 25 EST
Atmospheric OH Rate Constant 2.65E-10 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.